Werewolf Therapeutics Is Developing Immunomodulatory Cancer Therapeutics

on

 Werewolf Therapeutics, Inc.


Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. They are leveraging our proprietary PREDATOR™ platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitation of conventional proinflammatory immune therapies. Our INDUKINE™ molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. The most advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) INDUKINE molecules for the treatment of solid tumors. We are continuing preclinical studies for both WTX-124 and WTX-330 and expect to advance each candidate in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor.

Pipeline




WTX-124
  • WTX-124 is a systemically-delivered, conditionally-activated Interleukin-2 (IL-2) INDUKINETM molecule that is being developed to minimize the severe toxicities that have been observed with recombinant IL-2 therapy and maximize clinical benefit when administered as monotherapy or in combination with checkpoint inhibitors in multiple tumor types.
  • Key features of WTX-124 include maintenance of full IL-2 potency, high affinity blockade of IL2 - IL2Rβ/IL2Rγ interaction in systemic circulation and non-tumor tissues, half-life extension for optimal tumor exposure and proprietary tumor-selective protease activation.
  • In preclinical studies, WTX-124 exhibits excellent anti-tumor activity with a favorable pharmacokinetic and tolerability profile. Efficacy is driven by the differentiation, activation and expansion of T effector and memory lymphocyte immune responses.
WTX-330
  •  WTX is a systemically-delivered, conditionally-activated Interleukin-12 (IL-12) INDUKINETM molecule that is being developed to minimize the severe toxicities that have been observed with recombinant IL-12 therapy and maximize clinical benefit when administered as monotherapy or in combination with checkpoint inhibitors in refractory and/or immunologically unresponsive tumors.
  • Key features of WTX-330 include high affinity blockade of IL-12 – IL-12R interaction in systemic circulation and non-tumor tissues, half-life extension for optimal tumor exposure and proprietary tumor-selective protease activation.
  • In preclinical studies, WTX-330 exhibits excellent anti-tumor activity and a favorable pharmacokinetic and tolerability profile. Robust anti-tumor activity is mediated through stimulation of innate and adaptive antitumor immune responses - dendritic cell maturation and cross-presentation, Th1 differentiation and amplification of antitumor T effector cell responses.
WTX-613
  • WTX-613  is a systemically-delivered, conditionally-activated Interferon alpha (IFNα) INDUKINETM molecule that is being developed to minimize the severe toxicities that have been observed with recombinant IFNα therapy and maximize clinical benefit when administered as monotherapy or in combination with checkpoint inhibitors in refractory and/or immunologically unresponsive tumors.
  • Key features of our INDUKINETM molecule include high efficiency blockade of IFNα – IFNR interaction in systemic circulation and non-tumor tissues, half-life extension for optimal tumor exposure and proprietary tumor-selective protease activation.
  • In preclinical studies, WTX-613 exhibits robust anti-tumor activity mediated through stimulation of a type I interferon immune response with excellent pharmacokinetics and tolerability.

Comments

Post a Comment